NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
January 31, 2023 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating...
Mental Health Technologies Celebrates Mental Wellness Month
January 17, 2023 15:00 ET
|
Mental Health Technologies (MHT)
AURORA, Ill., Jan. 17, 2023 (GLOBE NEWSWIRE) -- At Mental Health Technologies (MHT), they bring awareness to mental health concerns daily. However, each year everyone goes from the hustle and bustle...
Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board
January 13, 2023 09:00 ET
|
Neurocentria, Inc
WALNUT CREEK, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Neurocentria, Inc., a privately held late-stage biotechnology company developing novel therapies for neurodegenerative and neuropsychiatric...
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
January 04, 2023 06:45 ET
|
Cingulate Inc.
Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04,...
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
December 05, 2022 08:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
December 01, 2022 14:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Participate in Benzinga All Live Access Event
November 30, 2022 15:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
November 14, 2022 06:45 ET
|
Cingulate Inc.
Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety...
NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
November 08, 2022 10:00 ET
|
NeuroSigma, Inc.
Trials recruiting subjects at UCLA and Seattle Children’s Hospital in the United States, and at King’s College London and the University of Southampton in the United Kingdom Trials sponsored by the...
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 03, 2022 16:30 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...